Johan Michiels

Research output

Research output per year 2004 2012 2016 2018 2021 2022 2023 2025

• 45 A1: Web of Science-article
• 3 Letter
• 2 Meeting abstract in journal

Research output per year

Research output per year

Search results

• 2025

  COVID-19 vaccine responses are influenced by distinct risk factors in naive and SARS-CoV-2 experienced hemodialysis recipients

  Gemander, N., Kemlin, D., Depickère, S., Kelkar, NS., Sharma, S., Pannus, P., Waegemans, A., Olislagers, V., Georges, D., Dhondt, E., Braga, M., Heyndrickx, L., Michiels, J., Thiriard, A., Lemy, A., Baudoux, T., Vandevenne, M., Goossens, ME., Matagne, A., Desombere, I., & 4 othersAriën, KK., Ackerman, ME., Le Moine, A. & Marchant, A., 2025, In: Vaccine. 44, 11 p., 126544.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access
• 2024

  Hybrid immunity overcomes defective immune response to COVID-19 vaccination in kidney transplant recipients

  Gemander, N., Kemlin, D., Depickère, S., Kelkar, NS., Pannus, P., Sharma, S., Waegemans, A., Olislagers, V., Georges, D., Dhondt, E., Braga, M., Heyndrickx, L., Michiels, J., Thiriard, A., Lemy, A., Vandevenne, M., Goossens, ME., Matagne, A., Desombere, I., Ariën, KK., & 3 othersAckerman, ME., Le Moine, A. & Marchant, A., 2024, In: Kidney International Reports. 9, 3, p. 635-648 14 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  • SARS Virus 100%
  • Kidney 58%
  • Mycophenolic Acid 15%
  • Kidney Transplantation 12%
  • Immunosuppressive Agents 11%

• Serological Evidence of Cryptic Rift Valley Fever Virus Transmission Among Humans and Livestock in Central Highlands of Kenya

  Situma, S., Omondi, E., Nyakarahuka, L., Odinoh, R., Mweu, M., Mureithi, MW., Mulinge, MM., Clancey, E., Dawa, J., Ngere, I., Osoro, E., Gunn, B., Konongoi, L., Khamadi, SA., Michiels, J., Ariën, KK., Bakamutumaho, B., Breiman, RF. & Njenga, K., 2024, In: Viruses. 16, 12, 14 p., 1927.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access
• 2023

  Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients

  Kemlin, D., Gemander, N., Depickère, S., Olislagers, V., Georges, D., Waegemans, A., Pannus, P., Lemy, A., Goossens, M. E., Desombere, I., Michiels, J., Vandevenne, M., Heyndrickx, L., Ariën, K. K., Matagne, A., Ackerman, M. E., Le Moine, A. & Marchant, A., 2023, In: American Journal of Transplantation. 23, 5, p. 649-658 10 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • SARS Virus 100%
  • Kidney 36%
  • Infections 32%
  • Interferon-gamma 30%
  • Vulnerable Populations 17%
  43 Downloads (Pure)

• Inactivation of SARS-CoV-2 and other enveloped and non-enveloped viruses with non-thermal plasma for hospital disinfection

  Sahun, M., Privat-Maldonado, A., Lin, A., De Roeck, N., Van der Heyden, L., Hillen, M., Michiels, J., Steenackers, G., Smits, E., Ariën, K. K., Jorens, P. G., Delputte, P. & Bogaerts, A., 2023, In: ACS sustainable chemistry & engineering. 11, 13, p. 5206-5215 10 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • Disinfection 94%
  • Viruses 76%
  • disinfection 63%
  • hospital 62%
  • Plasmas 59%
  132 Downloads (Pure)

• Presymptomatic viral shedding in high-risk contacts of monkeypox cases: a prospective cohort study

  ITM Monkeypox Study Group, 2023, In: Journal of Medical Virology. 95, 5, e28769.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • Virus Shedding 100%
  • Viruses 49%
  • Polymerase Chain Reaction 29%
  • Viral DNA 27%
  • Diaries 26%
  46 Downloads (Pure)

• Tecovirimat resistance in an immunocompromised patient with mpox and prolonged viral shedding

  Mertes, H., Rezende, A. M., Brosius, I., Naesens, R., Michiels, J., de Block, T., Coppens, J., Van Dijck, C., Bomans, P., Bottieau, E., Van Esbroeck, M., Ariën, K. K., Liesenborghs, L. & Vercauteren, K., 2023, In: Annals of Internal Medicine. 176, 8, p. 1141-1143 3 p.

  Research output: Contribution to journal › Letter › peer-review

  • Monkeypox virus 100%
  • Virus Shedding 79%
  • Virus Diseases 21%
  • Fissure in Ano 21%
  • Cryptococcus neoformans 18%

• Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults

  Pannus, P., Depickère, S., Kemlin, D., Georges, D., Houben, S., Olislagers, V., Waegemans, A., De Craeye, S., Francotte, A., Chaumont, F., Van Oostveldt, C., Heyndrickx, L., Michiels, J., Willems, E., Dhondt, E., Krauchuk, M., Schmickler, M-N., Verbrugghe, M., Van Loon, N., Dierick, K., & 5 othersMatagne, A., Desombere, I., Ariën, K. K., Marchant, A. & Goossens, M. E., 2023, In: Vaccine. 41, 17, p. 2829-2836 8 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • nursing home 100%
  • resident 63%
  • SARS Virus 53%
  • staff 43%
  • Infections 34%
  57 Downloads (Pure)

• Validation of a reporter cell line for flavivirus inhibition assays

  Rezende, T. M. T., Macera, G., Heyndrickx, L., Michiels, J., Coppens, S., Thibaut, H. J., Dallmeier, K., Van Esbroeck, M., Neyts, J., Ariën, K. K. & Bartholomeeusen, K., 2023, In: Microbiology Spectrum. 11, 2, 10 p., e0502722.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • assay 100%
  • cell 72%
  • Cell Line 69%
  • Dengue Virus 27%
  • antibody 24%
  70 Downloads (Pure)
• 2022

  A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell mediated immunity

  McCafferty, S., Haque, A. A., Vandierendonck, A., Weidensee, B., Plovyt, M., Stuchlíková, M., François, N., Valembois, S., Heyndrickx, L., Michiels, J., Ariën, K. K., Vandekerckhove, L., Abdelnabi, R., Foo, C. S., Neyts, J., Sahu, I. & Sanders, N. N., 2022, In: Molecular Therapy. 30, 9, p. 2968-2983 16 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • SARS Virus 100%
  • Antigen 56%
  • Dose 25%
  • Viral Load 13%
  52 Downloads (Pure)

• Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients

  Canti, L., Ariën, K. K., Desombere, I., Humblet-Baron, S., Pannus, P., Heyndrickx, L., Henry, A., Servais, S., Willems, E., Ehx, G., Goriely, S., Seidel, L., Michiels, J., Willems, B., Goossens, M. E., Beguin, Y., Marchant, A. & Baron, F., 2022, In: Cancer Cell. 40, 4, p. 335-337 3 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File
  43 Downloads (Pure)

• Poor antibody response to BioNTech/Pfizer COVID-19 vaccination in SARS-CoV-2 naïve residents of nursing homes

  Pannus, P., Neven, K. Y., De Craeye, S., Heyndrickx, L., Vande Kerckhove, S., Georges, D., Michiels, J., Francotte, A., Van Den Bulcke, M., Zrein, M., Van Gucht, S., Schmickler, M-N., Verbrugghe, M., Matagne, A., Thomas, I., Dierick, K., Weiner, J. A., Ackerman, M. E., Goriely, S., Goossens, M. E., & 3 othersAriën, K. K., Desombere, I. & Marchant, A., 2022, In: Clinical Infectious Diseases. 75, 1, p. e695–e704 10 p., ciab998.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  • SARS Virus 100%
  • Infections 10%
  28 Downloads (Pure)

• Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium

  ITM Monkeypox Study Group, 2022, In: Nature Medicine. 28, 11, p. 2288-2292 5 p., 1081.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • Monkeypox virus 100%
  • Sampling 48%
  • Virus Diseases 43%
  • Time 21%
  • Gonorrhea 11%
  70 Downloads (Pure)

• Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial

  Pannus, P., Depickère, S., Kemlin, D., Houben, S., Neven, K. Y., Heyndrickx, L., Michiels, J., Willems, E., De Craeye, S., Francotte, A., Chaumont, F., Olislagers, V., Waegemans, A., Verbrugghe, M., Schmickler, M-N., Van Gucht, S., Dierick, K., Marchant, A., Desombere, I., Ariën, K. K., & 1 othersGoossens, M. E., 2022, In: PLoS Global Public Health. 2, 12, p. e0001308 17 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • anti-IgG 100%
  • Income 73%
  • Infections 21%
  51 Downloads (Pure)

• Severe mpox (formerly monkeypox) disease in five patients after recent vaccination with MVA-BN vaccine, Belgium, July to October 2022

  ITM Monkeypox Study Group, 2022, In: Eurosurveillance. 27, 48, 6 p., 2200894.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • MVA vaccine 100%
  • vaccination 58%
  • Belgium 51%
  • Belgian 14%
  • Health Personnel 11%
  23 Downloads (Pure)

• Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant

  Ariën, K. K., Heyndrickx, L., Michiels, J., Vereecken, K., Van Lent, K., Coppens, S., Willems, B., Pannus, P., Martens, G. A., Van Esbroeck, M., Goossens, M. E., Marchant, A., Bartholomeeusen, K. & Desombere, I., 2022, In: Vaccines. 7, 1, 3 p., 35.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • SARS Virus 100%
  • Dose 51%
  • Infections 32%
  56 Downloads (Pure)
• 2021

  A dynamic mucin mRNA signature associates with COVID-19 disease presentation and severity

  Smet, A., Breugelmans, T., Michiels, J., Lamote, K., Arras, W., De Man, J. G., Heyndrickx, L., Hauner, A., Huizing, M., Malhotra-Kumar, S., Lammens, M., Hotterbeekx, A., Kumar-Singh, S., Verstraeten, A., Loeys, B., Verhoeven, V., Jacobs, R., Dams, K., Coenen, S., Ariën, K. K., & 2 othersJorens, P. G. & De Winter, B. Y., 2021, In: JCI insight. 6, 19, e151777.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • SARS Virus 100%
  • GS-5734 72%
  • baricitinib 61%
  • favipiravir 60%
  • tocilizumab 47%
  73 Downloads (Pure)

• Dynamics of the magnitude, breadth and depth of the antibody response at epitope level following dengue infection

  Falconi-Agapito, F., Kerkhof, K., Merino, X., Michiels, J., Van Esbroeck, M., Bartholomeeusen, K., Talledo, M. & Ariën, K. K., 2021, In: Frontiers in Immunology. 12, 21 p., 686691.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • Infections 100%
  • Proteome 93%
  • Peru 75%
  • Coinfection 58%
  • Yellow fever virus 44%
  79 Downloads (Pure)

• Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay

  Mariën, J., Ceulemans, A., Michiels, J., Heyndrickx, L., Kerkhof, K., Foque, N., Widdowson, M-A., Mortgat, L., Duysburgh, E., Desombere, I., Jansens, H., Van Esbroeck, M. & Ariën, K. K., 2021, In: Journal of Virological Methods. 288, 6 p., 114025.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • Coronavirus nucleocapsid protein 100%
  • Severe Acute Respiratory Syndrome 72%
  • Nucleocapsid 49%
  • Viruses 24%
  • Neutralization Tests 24%
  40 Downloads (Pure)

• Evaluation of a surrogate virus neutralization test for high-throughput serosurveillance of SARS-CoV-2

  Mariën, J., Michiels, J., Heyndrickx, L., Nkuba-Ndaye, A., Ceulemans, A., Bartholomeeusen, K., Madinga, J., Mbala-Kingebeni, P., Vanlerberghe, V., Ahuka-Mundeke, S., Wang, L-F. & Ariën, K. K., 2021, In: Journal of Virological Methods. 297, 114228.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • SARS Virus 100%
  • Neutralization Tests 88%
  • Viruses 45%
  • Containment of Biohazards 31%
  • Democratic Republic of the Congo 30%

• Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients

  Canti, L., Humblet-Baron, S., Desombere, I., Neumann, J., Pannus, P., Heyndrickx, L., Henry, A., Servais, S., Willems, E., Ehx, G., Goriely, S., Seidel, L., Michiels, J., Willems, B., Liston, A., Ariën, K. K., Beguin, Y., Goossens, M. E., Marchant, A. & Baron, F., 2021, In: Journal of Hematology & Oncology. 14, 1, 12 p., 174.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • SARS Virus 100%
  • Flow Cytometry 10%
  • Infections 6%
  22 Downloads (Pure)
• 2020

  A new genetic variant of dengue serotype 2 virus circulating in the Peruvian Amazon

  Falconi-Agapito, F., Selhorst, P., Merino, X., Torres, F., Michiels, J., Fernandez, C., Talledo, M. & Ariën, K. K., 2020, In: International Journal of Infectious Diseases. 96, p. 136-138 3 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • Peru 100%
  • Dengue Virus 93%
  • Serogroup 71%
  • Viruses 52%
  24 Downloads (Pure)

• Two distinct lineages of chikungunya virus cocirculated in Aruba during the 2014-2015 epidemic

  Phadungsombat, J., Tuekprakhon, A., Cnops, L., Michiels, J., van den Berg, R., Nakayama, E. E., Shioda, T., Ariën, K. K. & Huits, R., 2020, In: Infection, Genetics and Evolution. 78, 7 p., 104129.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • Aruba 100%
  • chikungunya 78%
  • Chikungunya virus 69%
  • West Indies 28%
  • genotype 27%
  66 Downloads (Pure)
• 2019

  Challenges in diagnosing Zika-experiences from a reference laboratory in a non-endemic setting

  Van den Bossche, D., Michiels, J., Cnops, L., Foque, N., Meersman, K., Huits, R., Ariën, K. & Van Esbroeck, M., 2019, In: European Journal of Clinical Microbiology and Infectious Diseases. 38, 4, p. 771-778 8 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • Zika Virus 100%
  • False Positive Reactions 45%
  • Neutralization Tests 39%
  • Tropical Medicine 22%
  • Infections 21%
• 2018

  Broad-spectrum monoclonal antibodies against chikungunya virus structural proteins: promising candidates for antibody-based rapid diagnostic test development

  Tuekprakhon, A., Puiprom, O., Sasaki, T., Michiels, J., Bartholomeeusen, K., Nakayama, E. E., Meno, M. K., Phadungsombat, J., Huits, R., Ariën, K. K., Luplertlop, N., Shioda, T. & Leaungwutiwong, P., 2018, In: PLoS ONE. 13, 12, 30 p., e0208851.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • Chikungunya virus 100%
  • Routine Diagnostic Tests 67%
  • Western Equine Encephalomyelitis 14%
  • Eastern Equine Encephalomyelitis 14%
  • Venezuelan Equine Encephalitis Viruses 12%
  26 Downloads (Pure)

• Can Zika virus antibodies cross-protect against dengue virus?

  Ariën, K. K., Michiels, J., Foqué, N., Heyndrickx, L. & Van Esbroeck, M., 2018, In: The Lancet Global health. 6, 5, p. e494 1 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

  File
  69 Downloads (Pure)

• Pharmacodynamic activity of DS003, a novel gp120 blocker, when administered to women as a vaginal tablet

  Nuttall, J., Arien, K., Michiels, J., Krit, M., Vanham, G., van Tilburg, P., du Puy, L., van Niekerk, N. & Nel, A., 2018, In: AIDS Research and Human Retroviruses. 34, p. 341-341 1 p.

  Research output: Contribution to journal › Meeting abstract in journal

• Zika virus IgG in infants with microcephaly, Guinea-Bissau, 2016

  Rosenstierne, M. W., Schaltz-Buchholzer, F., Bruzadelli, F., Có, A., Cardoso, P., Jørgensen, C. S., Michiels, J., Heyndrickx, L., Ariën, K. K., Fischer, T. K. & Fomsgaard, A., 2018, In: Emerging Infectious Diseases. 24, 5, p. 948-950 3 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • Guinea-Bissau 100%
  • Zika Virus 82%
  • Mothers 19%
  40 Downloads (Pure)
• 2017

  Can a ZIKA IGM and IGG immunoblot replace the virus neutralisation test to confirm screening test results?

  Van den Bossche, D., Foque, N., Michiels, J., Ariën, K. K. & Van Esbroeck, M., 2017, In: Tropical Medicine and International Health. 22, p. 122-122 1 p.

  Research output: Contribution to journal › Meeting abstract in journal
• 2016

  2,6-Di(arylamino)-3-fluoropyridine derivatives as HIV non-nucleoside reverse transcriptase inhibitors

  Sergeyev, S., Yadav, A. K., Franck, P., Michiels, J., Lewi, P., Heeres, J., Vanham, G., Ariën, K. K., Vande Velde, C. M. L., De Winter, H. & Maes, B. U. W., 2016, In: Journal of Medicinal Chemistry. 59, 5, p. 1854-1868

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • Nonnucleoside Reverse Transcriptase Inhibitor 100%
  • Reverse Transcriptase Inhibitors 83%
  • 5-fluoropyrimidine 67%
  • Pyrimidine 61%
  • Amination 57%

• CD4-mimetic sulfopeptide conjugates display sub-nanomolar anti-HIV-1 activity and protect macaques against a SHIV162P3 vaginal challenge

  Ariën, K. K., Baleux, F., Desjardins, D., Porrot, F., Coïc, Y-M., Michiels, J., Bouchemal, K., Bonnaffé, D., Bruel, T., Schwartz, O., Le Grand, R., Vanham, G., Dereuddre-Bosquet, N. & Lortat-Jacob, H., 2016, In: Scientific Reports. 6, 13 p., 34829.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • HIV-1 100%
  • Inhibitory Concentration 50 51%
  • Ligands 40%
  • Peptides 36%
  375 Downloads (Pure)

• Inhibition of HIV virus by neutralizing Vhh attached to dual functional liposomes encapsulating dapivirine

  Wang, S. X., Michiels, J., Ariën, K. K., New, R., Vanham, G. & Roitt, I., 2016, In: Nanoscale Research Letters. 11, p. 350

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • Liposomes 100%
  • Antibodies 77%
  • Viruses 71%
  • Liposome 56%
  • Neutralization 17%
  55 Downloads (Pure)

• Resistance and cross-resistance profile of the diaryltriazine NNRTI and candidate microbicide UAMC01398

  Ariën, K. K., Venkatraj, M., Michiels, J., Joossens, J., Vereecken, K., Van der Veken, P., Heeres, J., De Winter, H., Heyndrickx, L., Augustyns, K. & Vanham, G., 2016, In: Journal of Antimicrobial Chemotherapy. 71, 5, p. 1159-1168

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  • Dapivirine 100%
  • Reverse Transcriptase Inhibitors 65%
  • Viruses 36%

• Specificity of Zika virus ELISA: interference with malaria [letter]

  Van Esbroeck, M., Meersman, K., Michiels, J., Ariën, K. K. & Van den Bossche, D., 2016, In: Eurosurveillance. 21, 21, 2 p., pii=30237.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

  File
  58 Downloads (Pure)
• 2015

  A cross-sectional analysis of selected genital tract immunological markers and molecular vaginal microbiota in Sub-Saharan African women with relevance to HIV risk and prevention

  Kyongo Karanja, J., Crucitti, T., Menten, J., Hardy, L., Cools, P., Michiels, J., Delany-Moretlwe, S., Mwaura, M., Ndayisaba, G., Joseph, S., Fichorova, R., van de Wijgert, J., Vanham, G., Ariën, K. K. & Jespers, V., 2015, In: Clinical and Vaccine Immunology. 22, 5, p. 526-538

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • Anti HIV 100%
  • Meso Isomer 90%
  • Bacterial Vaginosis 78%
  • Genitalia 75%
  • Biological Marker 73%
  173 Downloads (Pure)
• 2014

  Development and characterization of a solid dispersion film for the vaginal application of the anti-HIV microbicide UAMC01398

  Grammen, C., Van den Mooter, G., Appeltans, B., Michiels, J., Crucitti, T., Ariën, K., Augustyns, K., Augustijns, P. & Brouwers, J., 2014, In: International Journal of Pharmaceutics. 475, 1-2, p. 238-244 7 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • Anti HIV 89%
  • Antimicrobial Agent 51%
  • Reverse Transcriptase Inhibitors 44%
  • Ether 40%
  • Liquid Film 35%

• From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds

  Venkatraj, M., Ariën, K., Heeres, J., Joossens, J., Dirié, B., Lyssens, S., Michiels, J., Cos, P., Lewi, P. J., Vanham, G., Maes, L., Van der Veken, P. & Augustyns, K., 2014, In: Bioorganic and Medicinal Chemistry. 22, 19, p. 5241-5248 8 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • Antitrypanosomal 100%
  • Nonnucleoside Reverse Transcriptase Inhibitor 98%
  • Reverse Transcriptase Inhibitors 82%
  • Triazine 49%
  • HIV-1 Reverse Transcriptase Inhibitor 35%
  1 Downloads (Pure)
• 2013

  Diaryltriazine non-nucleoside reverse transcriptase inhibitors are potent candidates for pre-exposure prophylaxis in the prevention of sexual HIV transmission

  Ariën, K. K., Venkatraj, M., Michiels, J., Joossens, J., Vereecken, K., Van der Veken, P., Abdellati, S., Cuylaerts, V., Crucitti, T., Heyndrickx, L., Heeres, J., Augustyns, K., Lewi, P. J. & Vanham, G., 2013, In: Journal of Antimicrobial Chemotherapy. 68, 9, p. 2038-2047 10 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • Dapivirine 100%
  • Reverse Transcriptase Inhibitors 65%
  • Libraries 32%
  • Viruses 24%
  • Proof of Concept Study 22%

• Interfacial cavity filling to optimize CD4-mimetic miniprotein interactions with the HIV-1 surface protein

  Morellato-Castillo, L., Acharya, P., Combes, O., Michiels, J., Descours, A., Ramos, O. H., Yang, Y., Vanham, G., Ariën, K. K., Kwong, P. D., Martin, L. & Kessler, P., 2013, In: J Med Chem. 56, 12, p. 5033-5047 15 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • HIV-1 100%
  • Molecular Cluster 74%
  • 4-aminophenylalanine 64%
  • Phenylalanine Derivative 59%
  • Phenylalanine Residue 53%

• In vitro and ex vivo evaluation of polymeric nanoparticles for vaginal and rectal delivery of the anti-HIV drug dapivirine

  das Neves, J., Araujo, F., Andrade, F., Michiels, J., Ariën, K. K., Vanham, G., Amiji, M., Bahia, M. F. & Sarmento, B., 2013, In: Molecular Pharmaceutics. 10, 7, p. 2793-2807 15 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • Dapivirine 100%
  • Rectal 80%
  • Anti Human Immunodeficiency Virus Agent 79%
  • Nanoparticle 27%
  • Drug 22%
• 2012

  MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency

  Grupping, K., Selhorst, P., Michiels, J., Vereecken, K., Heyndrickx, L., Kessler, P., Vanham, G., Martin, L. & Ariën, K. K., 2012, In: Retrovirology. 9, 36, p. 1-16 16 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • HIV-1 100%
  • Viruses 28%
  • CD4 Antigens 18%
  • Clone Cells 11%
  64 Downloads (Pure)

• Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine

  das Neves, J., Michiels, J., Ariën, K. K., Vanham, G., Amiji, M., Bahia, M. F. & Sarmento, B., 2012, In: Pharmaceutical Research. 29, 6, p. 1468-1484 17 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • Dapivirine 100%
  • Antiretroviral 77%
  • Antimicrobial Agent 38%
  • Drug 28%
  • Nanoparticle 27%

• Searching for lower female genital tract soluble and cellular biomarkers: defining levels and predictors in a cohort of healthy Caucasian women

  Kyongo, J. K., Jespers, V., Goovaerts, O., Michiels, J., Menten, J., Fichorova, R. N., Crucitti, T., Vanham, G. & Ariën, K. K., 2012, In: PLoS ONE. 7, 8, p. e43951

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • Female Genitalia 100%
  • Elafin 35%
  • Activity Cycles 29%
  • Prostate-Specific Antigen 21%
  • Immunoassay 20%
  34 Downloads (Pure)

• Synthesis, evaluation and structure-activity relationships of triazine dimers as novel antiviral agents

  Venkatraj, M., Ariën, K. K., Heeres, J., Joossens, J., Messagie, J., Michiels, J., Van der Veken, P., Vanham, G., Lewi, P. J. & Augustyns, K., 2012, In: Bioorganic and Medicinal Chemistry Letters. 22, 23, p. 7174-7178 5 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • Antiviral Agent 100%
  • Triazine 85%
  • Structure-Activity Relationship 66%
  • HIV-1 33%
  • Ligands 27%
• 2011

  Human Immunodeficiency Virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides

  Selhorst, P., Vazquez, AC., Terrazas-Aranda, K., Michiels, J., Vereecken, K., Heyndrickx, L., Weber, J., Quiñones-Mateu, ME., Ariën, KK. & Vanham, G., 2011, In: Antimicrobial Agents and Chemotherapy. 55, 4, p. 1403-1413 11 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  File

  • Reverse Transcriptase Inhibitors 100%
  • HIV-1 72%
  • UC 781 53%
  • Nevirapine 24%
  • Viruses 24%
  55 Downloads (Pure)

• Novel diarylpyridinones, diarylpyridazinones and diarylphthalazinones as potential HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs) [letter]

  Venkatraj, M., Ariën, KK., Heeres, J., Dirié, B., Joossens, J., Van Goethem, S., Van der Veken, P., Michiels, J., Vande Velde, CML., Vanham, G., Lewi, PJ. & Augustyns, K., 2011, In: Bioorganic and Medicinal Chemistry. 19, 20, p. 5924-5934 11 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • Nonnucleoside Reverse Transcriptase Inhibitor 100%
  • Human immunodeficiency virus 1 reverse transcriptase 95%
  • Reverse Transcriptase Inhibitors 83%
  • HIV-1 60%
  • Strain 48%
• 2008

  CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides

  Van Herrewege, Y., Morellato, L., Descours, A., Aerts, L., Michiels, J., Heyndrickx, L., Martin, L. & Vanham, G., 2008, In: Journal of Antimicrobial Chemotherapy. 61, 4, p. 818-826 9 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review
• 2007

  A dual chamber model of female cervical mucosa for the study of HIV transmission and for the evaluation of candidate HIV microbicides

  Van Herrewege, Y., Michiels, J., Waeytens, A., De Boeck, G., Salden, E., Heyndrickx, L., van den Mooter, G., de Béthune, MP., Andries, K., Lewi, P., Praet, M. & Vanham, G., 2007, In: Antiviral Research. 74, 2, p. 111-124

  Research output: Contribution to journal › A1: Web of Science-article › peer-review
• 2004

  A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides

  Van Herrewege, Y., Vanham, G., Michiels, J., Fransen, K., Kestens, L., Andries, K., Janssen, P. & Lewi, P., 2004, In: Antimicrobial Agents and Chemotherapy. 48, 10, p. 3684-3689

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

• In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides

  Van Herrewege, Y., Michiels, J., Van Roey, J., Fransen, K., Kestens, L., Balzarini, J., Lewi, P., Vanham, G. & Janssen, P., 2004, In: Antimicrobial Agents and Chemotherapy. 48, 1, p. 337-339

  Research output: Contribution to journal › A1: Web of Science-article › peer-review